<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639249</url>
  </required_header>
  <id_info>
    <org_study_id>ME1-2</org_study_id>
    <secondary_id>EudraCT number: 2007-004840-60</secondary_id>
    <nct_id>NCT00639249</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy Study of SA4503 in Subjects Recovering From Ischemic Stroke</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Phase IIa Study of Safety and Motor Function Restoration in Subjects Treated With SA4503 Following Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M's Science Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M's Science Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of SA4503 in patients
      recovering from a recent stroke. Secondary, to evaluate the efficacy of SA4503 compared to
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Further study details as provided by M's Science Corporation:
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIHSS</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SA4503</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SA4503</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SA4503 Low</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SA4503 High</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>A2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Males or females 18 years of age or older

          -  Experienced a stroke from 48 to 72 hours before randomization

          -  A total score of &gt;/=4 on the NIHSS, or &gt;/=2 on the upper or lower extremity motor
             scores of the NIHSS

          -  Medically and neurologically stable within 24 hours prior to randomization

        Key Exclusion Criteria:

          -  Patients with transient ischemic attack

          -  Patients with stroke in progression

          -  Unstable cardiac, hepatic, or renal disease, or other major medical disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith W Muir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern General Hospital, Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern General Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2008</study_first_submitted>
  <study_first_submitted_qc>March 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>July 28, 2009</last_update_submitted>
  <last_update_submitted_qc>July 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kazumasa Takao</name_title>
    <organization>M's Science Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>SA 4503</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

